SCREENING FOR EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS ASSOCIATED TO TYROSINE-KINASE INHIBITORS IN LUNG ADENOCARCINOMA PATIENTS FROM ARGENTINA

被引：0
|
作者：
Poleri, Claudia [1 ]
Castro, Marcelo [2 ]
Guasti, Marcelo [3 ]
Plotquin, Martin [3 ]
Bramuglia, Guillermo F.
机构：
[1] Fdn Investigar, Buenos Aires, DF, Argentina
[2] Uba Fdn Investigar, Area Hematol, Fac Farm & Bioquim, Buenos Aires, DF, Argentina
[3] AstraZeneca, Dept Med, Buenos Aires, DF, Argentina
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
EGFR; tirosine kinase inhibitors; Adenocarcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1017 / S1018
页数：2
相关论文
共 50 条
  • [1] Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
    Martinez-Marti, Alex
    Navarro, Alejandro
    Felip, Enriqueta
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S235 - S246
  • [2] Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
    Park, Sojung
    Lee, Sung Yong
    Kim, Dojin
    Sim, Yun Su
    Ryu, Jeong-Seon
    Choi, Juwhan
    Lee, Su Hwan
    Ryu, Yon Ju
    Lee, Jin Hwa
    Chang, Jung Hyun
    BMC CANCER, 2021, 21 (01)
  • [3] Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
    Sojung Park
    Sung Yong Lee
    Dojin Kim
    Yun Su Sim
    Jeong-Seon Ryu
    Juwhan Choi
    Su Hwan Lee
    Yon Ju Ryu
    Jin Hwa Lee
    Jung Hyun Chang
    BMC Cancer, 21
  • [4] Epidermal Growth Factor Receptor Mutations as a Prognostic Factor in Korean Patients with Advanced Lung Adenocarcinoma Who Had Not Been Treated with Received Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Kim, Seung Tae
    Choi, Yoon Ji
    Park, Kyong Hwa
    Oh, Sang Cheul
    Seo, Jae Hong
    Shin, Sang Won
    Kim, Jun Suk
    Kim, Yeul Hong
    CHEMOTHERAPY, 2011, 57 (02) : 108 - 114
  • [5] Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma
    徐含烟
    ChinaMedicalAbstracts(InternalMedicine), 2019, 36 (02) : 103 - 104
  • [6] Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation
    Baldini, Editta
    Prochilo, Tiziana
    Boldrini, Laura
    Melfi, Franca
    Fontanini, Gabriella
    MOLECULAR MEDICINE REPORTS, 2008, 1 (01) : 41 - 43
  • [7] MODERN VECTOR IN TREATMENT OF PATIENTS WITH LUNG CANCER: TYROSINE KINASE INHIBITORS IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
    Smorodska, O. M.
    Moskalenko, Yu, V
    Vynnychenko, I. O.
    Vynnychenko, O., I
    Kostuchenko, V. V.
    MEDICNI PERSPEKTIVI, 2021, 26 (02): : 4 - 11
  • [8] Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations
    Zeng, Zhu
    Chen, Hua-jun
    Yan, Hong-hong
    Yang, Jin-ji
    Zhang, Xu-chao
    Wu, Yi-long
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2013, 28 (03): : 249 - 258
  • [9] Prognostic Values of Inflammatory Indexes and Clinical Factors in Patients with Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma and Treated with Tyrosine Kinase Inhibitors
    Chang, Bee-Song
    Peng, Tai-Chu
    Wu, Yi-Feng
    Hsieh, Tsung-Cheng
    Huang, Chun-Hou
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (03):
  • [10] Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Jaenne, Pasi A.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4416S - 4420S
12345